CITADEL-204: parsaclisib in R/R MZL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, shares results of the primary analysis of the cohort of Bruton's tyrosine kinase (BTK) inhibitor-naive patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) treated with parsaclisib in the Phase II CITADEL-204 study (NCT03144674). In total, 100 patients were enrolled and allocated to receive parsaclisib 20 mg once daily for eight weeks, followed by either 20 mg once weekly or 2.5 mg once daily. The study demonstrated a rapid and durable response to parsaclisib in multiple subtypes of MZL. Additionally, the PI3Kδ inhibitor was generally well tolerated with a manageable safety profile. Overall, these results suggest that parsaclisib may be a potential treatment for R/R MZL, where few agents are approved. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Смотрите видео CITADEL-204: parsaclisib in R/R MZL онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 07 Январь 2022, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 22 раз и оно понравилось 0 людям.